TY - JOUR AU - Prat, A. AU - Baselga, J. PY - 2008 DA - 2008// TI - The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 JO - Nat Clin Pract Oncol VL - 5 UR - https://doi.org/10.1038/ncponc1179 DO - 10.1038/ncponc1179 ID - Prat2008 ER - TY - JOUR AU - Dawood, S. AU - Broglio, K. AU - Buzdar, A. U. AU - Hortobagyi, G. N. AU - Giordano, S. H. PY - 2010 DA - 2010// TI - Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review JO - J Clin Oncol. VL - 28 UR - https://doi.org/10.1200/JCO.2008.19.9844 DO - 10.1200/JCO.2008.19.9844 ID - Dawood2010 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. AU - Schwartz, J. N. AU - Hagerty, K. L. AU - Allred, D. C. AU - Cote, R. J. PY - 2007 DA - 2007// TI - American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer JO - J Clin Oncol. VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.2775 DO - 10.1200/JCO.2006.09.2775 ID - Wolff2007 ER - TY - JOUR AU - Pusztai, L. AU - Viale, G. AU - Kelly, C. M. AU - Hudis, C. A. PY - 2010 DA - 2010// TI - Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis JO - Oncologist. VL - 15 UR - https://doi.org/10.1634/theoncologist.2010-0059 DO - 10.1634/theoncologist.2010-0059 ID - Pusztai2010 ER - TY - JOUR AU - Yeung, C. AU - Hilton, J. AU - Clemons, M. AU - Mazzarello, S. AU - Hutton, B. AU - Haggar, F. PY - 2016 DA - 2016// TI - Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review JO - Cancer Metastasis Rev. VL - 35 UR - https://doi.org/10.1007/s10555-016-9631-3 DO - 10.1007/s10555-016-9631-3 ID - Yeung2016 ER - TY - JOUR AU - Dieci, M. V. AU - Barbieri, E. AU - Piacentini, F. AU - Ficarra, G. AU - Bettelli, S. AU - Dominici, M. PY - 2013 DA - 2013// TI - Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis JO - Ann Oncol. VL - 24 UR - https://doi.org/10.1093/annonc/mds248 DO - 10.1093/annonc/mds248 ID - Dieci2013 ER - TY - JOUR AU - Hoefnagel, L. D. AU - Moelans, C. B. AU - Meijer, S. L. AU - Slooten, H. J. AU - Wesseling, P. AU - Wesseling, J. PY - 2012 DA - 2012// TI - Prognostic value of estrogen receptor alpha and progesterone receptor conversion in distant breast cancer metastases JO - Cancer. VL - 118 UR - https://doi.org/10.1002/cncr.27518 DO - 10.1002/cncr.27518 ID - Hoefnagel2012 ER - TY - JOUR AU - Hoefnagel, L. D. AU - Vijver, M. J. AU - Slooten, H. J. AU - Wesseling, P. AU - Wesseling, J. AU - Westenend, P. J. PY - 2010 DA - 2010// TI - Receptor conversion in distant breast cancer metastases JO - Breast Cancer Res. VL - 12 UR - https://doi.org/10.1186/bcr2645 DO - 10.1186/bcr2645 ID - Hoefnagel2010 ER - TY - JOUR AU - Niikura, N. AU - Liu, J. AU - Hayashi, N. AU - Mittendorf, E. A. AU - Gong, Y. AU - Palla, S. L. PY - 2012 DA - 2012// TI - Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors JO - J Clin Oncol. VL - 30 UR - https://doi.org/10.1200/JCO.2010.33.8889 DO - 10.1200/JCO.2010.33.8889 ID - Niikura2012 ER - TY - JOUR AU - Amir, E. AU - Miller, N. AU - Geddie, W. AU - Freedman, O. AU - Kassam, F. AU - Simmons, C. PY - 2012 DA - 2012// TI - Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer JO - J Clin Oncol. VL - 30 UR - https://doi.org/10.1200/JCO.2010.33.5232 DO - 10.1200/JCO.2010.33.5232 ID - Amir2012 ER - TY - JOUR AU - Zidan, J. AU - Dashkovsky, I. AU - Stayerman, C. AU - Basher, W. AU - Cozacov, C. AU - Hadary, A. PY - 2005 DA - 2005// TI - Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease JO - Br J Cancer. VL - 93 UR - https://doi.org/10.1038/sj.bjc.6602738 DO - 10.1038/sj.bjc.6602738 ID - Zidan2005 ER - TY - JOUR AU - Poznak, C. AU - Somerfield, M. R. AU - Bast, R. C. AU - Cristofanilli, M. AU - Goetz, M. P. AU - Gonzalez-Angulo, A. M. PY - 2015 DA - 2015// TI - Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline JO - J Clin Oncol. VL - 33 UR - https://doi.org/10.1200/JCO.2015.61.1459 DO - 10.1200/JCO.2015.61.1459 ID - Poznak2015 ER - TY - JOUR AU - Duenas, E. M. AU - Hernandez, A. L. AU - Zotano, A. G. AU - Carrion, R. M. AU - Lopez-Muniz, J. I. AU - Novoa, S. A. PY - 2014 DA - 2014// TI - Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study JO - Breast Cancer Res Treat. VL - 143 UR - https://doi.org/10.1007/s10549-013-2825-2 DO - 10.1007/s10549-013-2825-2 ID - Duenas2014 ER - TY - STD TI - Schrijver W., Schuurman K., van Rossum A., Metastases Consortium D. Breast Cancer, Peeters T., Hoeve N. et al. Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. Oncotarget. 2017;8:55550-55561. ID - ref14 ER - TY - JOUR AU - Creighton, C. J. AU - Massarweh, S. AU - Huang, S. AU - Tsimelzon, A. AU - Hilsenbeck, S. G. AU - Osborne, C. K. PY - 2008 DA - 2008// TI - Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts JO - Cancer Res. VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-1404 DO - 10.1158/0008-5472.CAN-08-1404 ID - Creighton2008 ER - TY - JOUR AU - Massarweh, S. AU - Osborne, C. K. AU - Jiang, S. AU - Wakeling, A. E. AU - Rimawi, M. AU - Mohsin, S. K. PY - 2006 DA - 2006// TI - Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer JO - Cancer Res. VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-4045 DO - 10.1158/0008-5472.CAN-05-4045 ID - Massarweh2006 ER - TY - JOUR AU - Osborne, C. K. AU - Schiff, R. PY - 2011 DA - 2011// TI - Mechanisms of endocrine resistance in breast cancer JO - Annu Rev Med. VL - 62 UR - https://doi.org/10.1146/annurev-med-070909-182917 DO - 10.1146/annurev-med-070909-182917 ID - Osborne2011 ER - TY - JOUR AU - Linden, H. M. AU - Stekhova, S. A. AU - Link, J. M. AU - Gralow, J. R. AU - Livingston, R. B. AU - Ellis, G. K. PY - 2006 DA - 2006// TI - Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer JO - J Clin Oncol. VL - 24 UR - https://doi.org/10.1200/JCO.2005.04.3810 DO - 10.1200/JCO.2005.04.3810 ID - Linden2006 ER - TY - JOUR AU - Mortimer, J. E. AU - Dehdashti, F. AU - Siegel, B. A. AU - Trinkaus, K. AU - Katzenellenbogen, J. A. AU - Welch, M. J. PY - 2001 DA - 2001// TI - Metabolic flare: indicator of hormone responsiveness in advanced breast cancer JO - J Clin Oncol. VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.11.2797 DO - 10.1200/JCO.2001.19.11.2797 ID - Mortimer2001 ER - TY - JOUR AU - Ulaner, G. A. AU - Hyman, D. M. AU - Ross, D. S. AU - Corben, A. AU - Chandarlapaty, S. AU - Goldfarb, S. PY - 2016 DA - 2016// TI - Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT JO - J Nucl Med. VL - 57 UR - https://doi.org/10.2967/jnumed.115.172031 DO - 10.2967/jnumed.115.172031 ID - Ulaner2016 ER - TY - JOUR AU - Duffy, M. J. AU - Harbeck, N. AU - Nap, M. AU - Molina, R. AU - Nicolini, A. AU - Senkus, E. PY - 2017 DA - 2017// TI - Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM) JO - Eur J Cancer. VL - 75 UR - https://doi.org/10.1016/j.ejca.2017.01.017 DO - 10.1016/j.ejca.2017.01.017 ID - Duffy2017 ER - TY - JOUR AU - Benard, F. AU - Ahmed, N. AU - Beauregard, J. M. AU - Rousseau, J. AU - Aliaga, A. AU - Dubuc, C. PY - 2008 DA - 2008// TI - [18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice JO - Eur J Nucl Med Mol Imaging. VL - 35 UR - https://doi.org/10.1007/s00259-008-0745-x DO - 10.1007/s00259-008-0745-x ID - Benard2008 ER - TY - JOUR AU - Paquette, M. AU - Phoenix, S. AU - Ouellet, R. AU - Langlois, R. AU - Lier, J. E. AU - Turcotte, E. E. PY - 2013 DA - 2013// TI - Assessment of the novel estrogen receptor PET tracer 4-fluoro-11beta-methoxy-16alpha-[18F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model JO - Mol Imaging Biol. VL - 15 UR - https://doi.org/10.1007/s11307-013-0638-7 DO - 10.1007/s11307-013-0638-7 ID - Paquette2013 ER - TY - JOUR AU - Paquette, M. AU - Lavallee, E. AU - Phoenix, S. AU - Ouellet, R. AU - Senta, H. AU - Lier, J. E. PY - 2018 DA - 2018// TI - Improved estrogen receptor assessment by PET using the novel radiotracer 18F-4FMFES in estrogen receptor-positive breast cancer patients: an ongoing phase II clinical trial JO - J Nucl Med. VL - 59 UR - https://doi.org/10.2967/jnumed.117.194654 DO - 10.2967/jnumed.117.194654 ID - Paquette2018 ER - TY - JOUR AU - Barok, M. AU - Joncour, V. AU - Martins, A. AU - Isola, J. AU - Salmikangas, M. AU - Laakkonen, P. PY - 2020 DA - 2020// TI - ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer JO - Cancer Lett. VL - 473 UR - https://doi.org/10.1016/j.canlet.2019.12.037 DO - 10.1016/j.canlet.2019.12.037 ID - Barok2020 ER - TY - JOUR AU - Alnahwi, A. H. AU - Tremblay, S. AU - Guerin, B. PY - 2018 DA - 2018// TI - Comparative study with 89Y-foil and 89Y-pressed targets for the production of 89Zr JO - Applied Sciences. VL - 8 UR - https://doi.org/10.3390/app8091579 DO - 10.3390/app8091579 ID - Alnahwi2018 ER - TY - JOUR AU - Ahmed, N. AU - Langlois, R. AU - Rodrigue, S. AU - Benard, F. AU - Lier, J. E. PY - 2007 DA - 2007// TI - Automated synthesis of 11beta-methoxy-4,16alpha-[16alpha-18F]difluoroestradiol (4F-M[18F]FES) for estrogen receptor imaging by positron emission tomography JO - Nucl Med Biol. VL - 34 UR - https://doi.org/10.1016/j.nucmedbio.2007.02.001 DO - 10.1016/j.nucmedbio.2007.02.001 ID - Ahmed2007 ER - TY - JOUR AU - Paquette, M. AU - Vilera-Perez, L. G. AU - Beaudoin, S. AU - Ekindi-Ndongo, N. AU - Boudreault, P. L. AU - Bonin, M. A. PY - 2017 DA - 2017// TI - Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer JO - Oncoimmunology. VL - 6 UR - https://doi.org/10.1080/2162402X.2017.1331195 DO - 10.1080/2162402X.2017.1331195 ID - Paquette2017 ER - TY - JOUR AU - Dijkers, E. C. AU - Kosterink, J. G. AU - Rademaker, A. P. AU - Perk, L. R. AU - Dongen, G. A. AU - Bart, J. PY - 2009 DA - 2009// TI - Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging JO - J Nucl Med. VL - 50 UR - https://doi.org/10.2967/jnumed.108.060392 DO - 10.2967/jnumed.108.060392 ID - Dijkers2009 ER - TY - JOUR AU - Holland, J. P. AU - Divilov, V. AU - Bander, N. H. AU - Smith-Jones, P. M. AU - Larson, S. M. AU - Lewis, J. S. PY - 2010 DA - 2010// TI - 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo JO - J Nucl Med. VL - 51 UR - https://doi.org/10.2967/jnumed.110.076174 DO - 10.2967/jnumed.110.076174 ID - Holland2010 ER - TY - JOUR AU - Perk, L. R. AU - Visser, G. W. AU - Vosjan, M. J. AU - Stigter-van Walsum, M. AU - Tijink, B. M. AU - Leemans, C. R. PY - 2005 DA - 2005// TI - 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab JO - J Nucl Med. VL - 46 ID - Perk2005 ER - TY - JOUR AU - Ulaner, G. A. AU - Hyman, D. M. AU - Lyashchenko, S. K. AU - Lewis, J. S. AU - Carrasquillo, J. A. PY - 2017 DA - 2017// TI - 89Zr-trastuzumab PET/CT for detection of human epidermal growth factor receptor 2–positive metastases in patients with human epidermal growth factor receptor 2–negative primary breast cancer JO - Clin Nucl Med. VL - 42 UR - https://doi.org/10.1097/RLU.0000000000001820 DO - 10.1097/RLU.0000000000001820 ID - Ulaner2017 ER - TY - JOUR AU - Fowler, A. M. AU - Chan, S. R. AU - Sharp, T. L. AU - Fettig, N. M. AU - Zhou, D. AU - Dence, C. S. PY - 2012 DA - 2012// TI - Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer JO - J Nucl Med. VL - 53 UR - https://doi.org/10.2967/jnumed.112.103465 DO - 10.2967/jnumed.112.103465 ID - Fowler2012 ER - TY - JOUR AU - Henry, K. E. AU - Dilling, T. R. AU - Abdel-Atti, D. AU - Edwards, K. J. AU - Evans, M. J. AU - Lewis, J. S. PY - 2018 DA - 2018// TI - Noninvasive 89Zr-transferrin PET shows improved tumor targeting compared with 18F-FDG PET in MYC-overexpressing human triple-negative breast cancer JO - J Nucl Med. VL - 59 UR - https://doi.org/10.2967/jnumed.117.192286 DO - 10.2967/jnumed.117.192286 ID - Henry2018 ER - TY - JOUR AU - Theze, B. AU - Bernards, N. AU - Beynel, A. AU - Bouet, S. AU - Kuhnast, B. AU - Buvat, I. PY - 2015 DA - 2015// TI - Monitoring therapeutic efficacy of sunitinib using [18F]FDG and [18F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma JO - BMC Cancer. VL - 15 UR - https://doi.org/10.1186/s12885-015-1540-2 DO - 10.1186/s12885-015-1540-2 ID - Theze2015 ER - TY - JOUR AU - Janjigian, Y. Y. AU - Viola-Villegas, N. AU - Holland, J. P. AU - Divilov, V. AU - Carlin, S. D. AU - Gomes-DaGama, E. M. PY - 2013 DA - 2013// TI - Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET JO - J Nucl Med. VL - 54 UR - https://doi.org/10.2967/jnumed.112.110239 DO - 10.2967/jnumed.112.110239 ID - Janjigian2013 ER - TY - JOUR AU - Barok, M. AU - Tanner, M. AU - Koninki, K. AU - Isola, J. PY - 2011 DA - 2011// TI - Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo JO - Breast Cancer Res. VL - 13 UR - https://doi.org/10.1186/bcr2868 DO - 10.1186/bcr2868 ID - Barok2011 ER - TY - JOUR AU - Nagy, P. AU - Friedlander, E. AU - Tanner, M. AU - Kapanen, A. I. AU - Carraway, K. L. AU - Isola, J. PY - 2005 DA - 2005// TI - Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line JO - Cancer Res. VL - 65 ID - Nagy2005 ER - TY - JOUR AU - O'Donoghue, J. A. AU - Lewis, J. S. AU - Pandit-Taskar, N. AU - Fleming, S. E. AU - Schoder, H. AU - Larson, S. M. PY - 2018 DA - 2018// TI - Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer JO - J Nucl Med. VL - 59 UR - https://doi.org/10.2967/jnumed.117.194555 DO - 10.2967/jnumed.117.194555 ID - O'Donoghue2018 ER - TY - JOUR AU - Laforest, R. AU - Lapi, S. E. AU - Oyama, R. AU - Bose, R. AU - Tabchy, A. AU - Marquez-Nostra, B. V. PY - 2016 DA - 2016// TI - [89Zr]Trastuzumab:evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer JO - Mol Imaging Biol. VL - 18 UR - https://doi.org/10.1007/s11307-016-0951-z DO - 10.1007/s11307-016-0951-z ID - Laforest2016 ER - TY - STD TI - Srinivasan S, Crandall J, Gajwani P, Sgouros G, Mena E, Lodge MA, et al. Human radiation dosimetry of orally or intravenously administered 18F-fluorodeoxyglucose. J Nucl Med. 2019. https://doi.org/10.2967/jnumed. ID - ref41 ER - TY - JOUR AU - Beauregard, J. M. AU - Croteau, E. AU - Ahmed, N. AU - Lier, J. E. AU - Benard, F. PY - 2009 DA - 2009// TI - Assessment of human biodistribution and dosimetry of 4-fluoro-11β-methoxy-16α-18F-fluoroestradiol using serial whole-body PET/CT JO - J Nucl Med. VL - 50 UR - https://doi.org/10.2967/jnumed.108.057000 DO - 10.2967/jnumed.108.057000 ID - Beauregard2009 ER -